Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development
This article was originally published in RPM Report
A stakeholder project on obesity treatment outcomes will complete its work this summer, setting the stage for FDA to rethink efficacy endpoints for weight loss drug development. The closed-door project is happening in parallel with public advisory committee discussions on pending applications and safety standards. One impact will be to shape more formal patient-centered drug development activities in years to come.